Compare CWCO & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | ASMB |
|---|---|---|
| Founded | 1973 | 2005 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 512.1M |
| IPO Year | 1997 | 2010 |
| Metric | CWCO | ASMB |
|---|---|---|
| Price | $29.32 | $25.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $40.00 | ★ $44.20 |
| AVG Volume (30 Days) | 91.1K | ★ 231.8K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $132,073,368.00 | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $42.86 | $638.39 |
| P/E Ratio | $127.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.17 | $16.90 |
| 52 Week High | $39.12 | $39.71 |
| Indicator | CWCO | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 45.48 |
| Support Level | $29.18 | $21.80 |
| Resistance Level | $30.69 | $30.47 |
| Average True Range (ATR) | 0.50 | 1.40 |
| MACD | 0.09 | -0.24 |
| Stochastic Oscillator | 77.19 | 12.37 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.